Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (viaject™) in comparison to regular human insulin

Journal of Diabetes Science and Technology

Volumn 2, Issue 4, 2008, Pages 568-571

  Hompesch, Marcus ^a   McManus, Laura ^a   Pohl, Roderike ^b   Simms, Patrick ^b   Pfützner, Andreas ^c   Bülow, Elena ^b   Flacke, Frank ^b   Heinemann, Lutz ^d   Steiner, Solomon S ^b  

^a Profil Institute for Clinical Research   (United States)

^b Biodel Inc   (United States)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d Profil Institut fur Stoffwechselforschung   (Germany)

Author keywords

Human insulin; Insulin therapy; Prandial insulin; Rapid acting insulin analogs; Variability; Viaject

Indexed keywords

EID: 77956134435     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680800200406     Document Type: Article

References (5)

1. Heinemann L. Variability of Insulin Action: Does this matter? Insulin. 2008;3:37-45.
2. Heise T, Nosek L, Stender A, Biilmann Rønn B, Heinemann L, Kapitza C, Draeger E. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004 Jun; 53(6):1614-1620.
3. Pohl, R, Steiner SS, inventors; Biodel, Inc., assignee. Rapid acting drug delivery compositions. United States patent US 7279457. 2007 Oct. 9.
4. Steiner SS, Hompesch M, Pohl R, Simms P, Pfützner A, Heinemann L. A formulation of human insulin with a more rapid onset of action than rapid-acting insulin analogues. Diabetologia. In press 2008.
5. Heinemann L, Weyer C, Rave K, Stiefelhagen O, Rauhaus M, Heise T. Comparison of the time action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28 Asp. Exp Clin Endocrinol Diabetes. 1997;105:140-144.